ArticleOncology letters2017
'Obligate' anaerobic
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- In vitro and in vivo antitumor activity of Laz-expressing Salmonella Typhimurium YB1 via optimized secretion and regulation.AMB Express · 2026Article
- The amplification of bacteriophages using Salmonella YB1 as a host and its therapeutic efficacy against salmonellosis in broilers.Poultry science · 2026Article
- Research progress and clinical translation challenges in the use of oncolytic bacteria for cancer therapy.Medical oncology (Northwood, London, England) · 2026Review
- Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response.International journal of molecular sciences · 2025Review
- Bacteria-based immunosuppressive tumor microenvironment reprogramming: a promising dawn in cancer therapy.Microbial cell factories · 2025Review
- Resynthesis of synthetic biology techniques: combining engineered bacteria with other antitumour therapies.Frontiers in microbiology · 2025Review
- Intravital imaging reveals spatiotemporal dynamics of oncolyticFrontiers in immunology · 2025Article
- Attenuated mutants ofExperimental biology and medicine (Maywood, N.J.) · 2024Article
- Bacteria-Based Nanoprobes for Cancer Therapy.International journal of nanomedicine · 2024Review
- Bacterial Drug Delivery Systems for Cancer Therapy: "Why" and "How".Pharmaceutics · 2023Review
- Engineered Salmonella inhibits GPX4 expression and induces ferroptosis to suppress glioma growth in vitro and in vivo.Journal of neuro-oncology · 2023Article
- Targeted IFNγ induction by a genetically engineeredFrontiers in medicine · 2023Article
- Review
- Genetically engineered bacterium: Principles, practices, and prospects.Frontiers in microbiology · 2022Review
- Downregulation of AKT/mTOR signaling pathway forJournal of Cancer · 2022Article
- Integration ofCancers · 2021Review
- IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella.Nature communications · 2021Article
- Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-CancerFrontiers in immunology · 2021Article
- Perspectives on OncolyticFrontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antitumor properties of bacteria have been demonstrated over the past decades. However, the efficacy is limited and unclear. Furthermore, systemic infection remains a serious concern in bacteria treatment. In this study, the effect of YB1, a rationally designed 'obligate' anaerobic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.